MarketCapExport financials
Insulet Corporation (PODD)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Insulet Corporation Cash Flow 2025-2008 | PODD
Brief cash flow overview of Insulet Corporation
Cash flows are assessed across five available annual periods spanning 2021 to 2025.
Operating cash flow reversed from -$68.1 million to $569.3 million, improving the company's ability to fund itself.
Positive cash generation persisted in 4 of five years, so stability is not unconditional.
Operating cash flow covered cumulative profit by 1.34x, providing strong cash confirmation.
Operating cash flow margin improved from -6.2% to 21%. The quality of revenue growth strengthened.
Cash flow takeaway
Insulet Corporation's cash flow sends more positive than negative signals, but receipt quality should be confirmed in future reports.
Annual Cash Flow Insulet Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
569 M | 430 M | 146 M | 119 M | -68.1 M | 84 M | 98.4 M | 35.9 M | 41.3 M | 15.9 M | -12.6 M | 8.92 M | 3.35 M | -29.1 M | -25.5 M | -35.6 M | -49.3 M | - |
Depreciation & Amortization |
90.4 M | 80.8 M | 72.8 M | 63.2 M | 57.4 M | 55.4 M | 27.9 M | 15.6 M | 13.9 M | 13.8 M | 15.8 M | 12.2 M | 11.8 M | 11 M | 8.5 M | 5.08 M | 5.22 M | - |
Accounts Payables |
75 M | 19.8 M | 19.2 M | 30.8 M | 37.7 M | 54.1 M | 54.5 M | 25.5 M | 24.4 M | 13.2 M | 15.2 M | 14.7 M | 19.4 M | 9.36 M | 11.4 M | 4.9 M | - | - |
Accounts Receivables |
- | - | - | 141 M | 135 M | 83.8 M | 69.3 M | 63.3 M | 53.4 M | 28.8 M | 42.5 M | 39.9 M | 33.1 M | 33.3 M | 23.2 M | 16.8 M | - | - |
Total Inventories |
453 M | 430 M | 403 M | 347 M | 303 M | 154 M | 101 M | 71.4 M | 33.8 M | 35.5 M | 12 M | 13.1 M | 9.46 M | 14.9 M | 11.8 M | 11.4 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Cash Flow Insulet Corporation
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | 88.4 M | 114 M | 183 M | 126 M | 196 M | 63.8 M | 148 M | 108 M | 86.8 M | 87.6 M | 45.2 M | 56 M | 44 M | 500 K | 50.7 M | 56.7 M | 25.3 M | -13.7 M | -25.5 M | -25.8 M | 18.3 M | -35.1 M | 17 M | 44.2 M | 26.4 M | -3.6 M | 46.9 M | 31.1 M | 13.9 M | 6.5 M | 30.4 M | 15.9 M | -6.13 M | -4.27 M | 21.9 M | 23.3 M | 18 M | -21.8 M | 20.1 M | 2.68 M | 3.68 M | -10.5 M | -18.6 M | 8.75 M | 785 K | -3.49 M | 4.61 M | 4.82 M | 508 K | -1.02 M | -3.52 M | 3.69 M | 4.37 M | -1.2 M | -5.59 M | -3.45 M | -11.1 M | -8.9 M | -7.67 M | -836 K | -16.9 M | -7.87 M |
Depreciation & Amortization |
- | 26.7 M | 26.2 M | 2.8 M | 2.7 M | 2.6 M | 2.4 M | 2.5 M | 2.5 M | 2.4 M | 2.4 M | 2.5 M | 2.6 M | 2.7 M | 2.4 M | 1.8 M | 1.9 M | 1.7 M | 1.8 M | 1.7 M | 1.6 M | 1.8 M | 1.7 M | 14.6 M | 700 K | 700 K | 800 K | 800 K | 700 K | 600 K | 600 K | 500 K | 500 K | 400 K | 400 K | 400 K | 300 K | 300 K | 300 K | 300 K | 300 K | 300 K | 100 K | 500 K | 500 K | 7.11 M | 3.43 M | -3.1 M | 900 K | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.3 M | 1.4 M | 1.4 M | 1.4 M | 1.5 M | 1.7 M | 1.7 M | 1.7 M | 500 K | 1.16 M |
Accounts Payables |
162 M | 123 M | 150 M | 75 M | 48.2 M | 96.1 M | 57.6 M | 19.8 M | 40.3 M | 76.8 M | 75.9 M | 19.2 M | 77.8 M | 108 M | 85.9 M | 30.8 M | 62.1 M | 6.1 M | 2.7 M | 4.7 M | 3.6 M | 4.5 M | 3.5 M | 7.1 M | 5.4 M | 4.7 M | 7.1 M | 2.4 M | 3.12 M | 3.09 M | 7.5 M | 7.7 M | 3.86 M | 3.65 M | 2.14 M | 3.54 M | 932 K | 741 K | 1.89 M | 2.89 M | 643 K | 2.81 M | 3.44 M | 4.98 M | 15.6 M | 17.9 M | 14.2 M | 1.85 M | 17.7 M | 18.6 M | 21 M | 19.4 M | 15.1 M | 11.4 M | 8.54 M | 9.36 M | 16.2 M | 13.7 M | 16.1 M | 11.4 M | 8.6 M | 9.37 M | 11.4 M |
Accounts Receivables |
689 M | 589 M | 545 M | 517 M | - | - | - | - | - | - | - | - | - | - | 160 M | 141 M | 153 M | 154 M | 154 M | 135 M | 114 M | 100 M | 97.9 M | 95.3 M | 85.4 M | 78 M | 80.1 M | 69.3 M | 65.1 M | 67 M | 68.7 M | 63.3 M | 70 M | 49.7 M | 50.4 M | 53.4 M | 47.2 M | 37.8 M | 40.6 M | 28.8 M | 38.5 M | 38.7 M | 40.5 M | 42.5 M | 31.8 M | 31.8 M | 36.1 M | 39.9 M | 47.1 M | 41.8 M | 36.7 M | 33.1 M | 34.5 M | 33.6 M | 31.1 M | 33.3 M | 30.1 M | 25.6 M | 26.2 M | 23.2 M | 17.3 M | 20.4 M | 23.2 M |
Total Inventories |
552 M | 485 M | 462 M | 453 M | 446 M | 447 M | 441 M | 430 M | 445 M | 431 M | 431 M | 403 M | 411 M | 411 M | 386 M | 347 M | 328 M | 320 M | 315 M | 303 M | 259 M | 198 M | 170 M | 154 M | 125 M | 104 M | 95.7 M | 101 M | 90.2 M | 85.1 M | 73.8 M | 71.4 M | 58 M | 40.8 M | 26.3 M | 33.8 M | 35.1 M | 34 M | 34.3 M | 35.5 M | 32.7 M | 24.5 M | 14 M | 12 M | 13 M | 23.4 M | 20.1 M | 13.1 M | 9.66 M | 8.76 M | 10.4 M | 9.46 M | 5.4 M | 5.98 M | 9.2 M | 14.9 M | 15.1 M | 16.4 M | 14.7 M | 11.8 M | 13.1 M | 16 M | 11.8 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Insulet Corporation, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Medical devices sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Abbott Laboratories
ABT
|
$ 110.59 | 0.07 % | $ 193 B |  USA |
 |
EDAP TMS S.A.
EDAP
|
- | - | $ 162 M |  France |
 |
Align Technology
ALGN
|
$ 174.54 | 0.16 % | $ 12.7 B | USA |
 |
TELA Bio
TELA
|
$ 0.83 | -4.37 % | $ 39 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
$ 104.0 | -0.68 % | $ 60.8 B | USA |
 |
Avinger
AVGR
|
- | -20.74 % | $ 369 K | USA |
 |
CONMED Corporation
CNMD
|
$ 51.21 | -1.42 % | $ 1.59 B | USA |
 |
Medtronic PLC
MDT
|
$ 101.59 | -1.17 % | $ 130 B | USA |
 |
MiMedx Group
MDXG
|
$ 3.37 | 1.36 % | $ 498 M | USA |
 |
ThermoGenesis Holdings
THMO
|
- | -25.84 % | $ 171 K | USA |
 |
Talis Biomedical Corporation
TLIS
|
- | 3.55 % | $ 7.96 M | USA |
 |
Myomo
MYO
|
$ 1.32 | -5.71 % | $ 55.2 M | USA |
 |
Profound Medical Corp.
PROF
|
$ 7.66 | 4.36 % | $ 232 M |  Canada |
 |
Quanterix Corporation
QTRX
|
$ 3.3 | -2.51 % | $ 141 M | USA |
 |
Viveve Medical
VIVE
|
- | -15.35 % | $ 1.71 M | USA |
 |
Smith & Nephew plc
SNN
|
$ 30.96 | -0.29 % | $ 26.8 B |  Britain |
 |
Sensus Healthcare
SRTS
|
$ 3.42 | 7.39 % | $ 55.8 M | USA |
 |
Stryker Corporation
SYK
|
$ 324.18 | -0.48 % | $ 124 B | USA |
 |
Tactile Systems Technology
TCMD
|
$ 26.61 | 0.08 % | $ 609 M | USA |
 |
TransMedics Group
TMDX
|
$ 91.02 | -2.95 % | $ 3.09 B | USA |
 |
SmileDirectClub
SDC
|
- | -53.45 % | $ 9.71 M | USA |
 |
Viemed Healthcare
VMD
|
$ 9.04 | 1.01 % | $ 352 M | USA |
 |
Varex Imaging Corporation
VREX
|
$ 18.45 | 0.03 % | $ 764 M | USA |
 |
Acutus Medical
AFIB
|
- | -26.83 % | $ 2.62 M | USA |
 |
Vivos Therapeutics
VVOS
|
$ 0.09 | -8.14 % | $ 925 K | USA |
 |
BIOLASE
BIOL
|
- | -13.19 % | $ 166 K | USA |
 |
SeaSpine Holdings Corporation
SPNE
|
- | 0.28 % | $ 270 M | USA |
 |
Xtant Medical Holdings
XTNT
|
$ 0.28 | -0.68 % | $ 39.1 M | USA |
 |
Zimmer Biomet Holdings
ZBH
|
$ 107.39 | -0.87 % | $ 21.3 B | USA |
 |
Apollo Endosurgery
APEN
|
- | - | $ 475 M | USA |
 |
NuVasive
NUVA
|
- | - | $ 2.07 B | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
$ 0.37 | 59.63 % | $ 24 M |  Israel |
 |
Penumbra
PEN
|
$ 321.48 | -0.11 % | $ 12.5 B | USA |
 |
Conformis
CFMS
|
- | - | $ 16.4 M | USA |
 |
ViewRay
VRAY
|
- | 1.54 % | $ 468 M | USA |
 |
Medigus Ltd.
MDGS
|
- | 10.28 % | $ 55.5 M | Israel |
 |
Boston Scientific Corporation
BSX
|
$ 44.68 | 1.49 % | $ 66.1 B | USA |
 |
Cutera
CUTR
|
- | -10.19 % | $ 1.99 M | USA |
 |
Neovasc
NVCN
|
- | - | $ 111 M | Canada |
 |
Vapotherm
VAPO
|
- | 6.72 % | $ 34 M | USA |
 |
Nevro Corp.
NVRO
|
- | - | $ 217 M | USA |
 |
Venus Concept
VERO
|
- | - | $ 726 K | USA |
 |
Eargo
EAR
|
- | - | $ 10.2 M | USA |
 |
Sientra
SIEN
|
- | -16.59 % | $ 10.3 M | USA |
 |
Silk Road Medical, Inc
SILK
|
- | - | $ 1.07 B | USA |
 |
Surgalign Holdings
SRGA
|
- | -32.98 % | $ 1.68 M | USA |
 |
Cardiovascular Systems
CSII
|
- | 0.15 % | $ 844 M | USA |
 |
ShockWave Medical
SWAV
|
- | - | $ 12.3 B | USA |
 |
Inari Medical
NARI
|
- | - | $ 4.23 B | USA |